Long-Term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for CD: Results From the VIVID-2 Open-Label Extension Study.
出版信息
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):17-18.
Abstract
摘要
相似文献
1
Long-Term Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for CD: Results From the VIVID-2 Open-Label Extension Study.
Gastroenterol Hepatol (N Y). 2025 Aug;21(7 Suppl 5):17-18.
2
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflamm Bowel Dis. 2024 Oct 25. doi: 10.1093/ibd/izae253.
3
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
Am J Gastroenterol. 2025 Mar 13;120(8):1809-19. doi: 10.14309/ajg.0000000000003410.
4
Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.
Clin Transl Sci. 2025 Aug;18(8):e70320. doi: 10.1111/cts.70320.
5
Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf100.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Am J Clin Dermatol. 2025 Jul 29. doi: 10.1007/s40257-025-00964-6.
8
Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants.
Adv Ther. 2025 Sep 3. doi: 10.1007/s12325-025-03335-z.
9
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Inflammopharmacology. 2025 Mar;33(3):1033-1042. doi: 10.1007/s10787-025-01658-5. Epub 2025 Feb 15.
10
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
Am J Clin Dermatol. 2025 Aug 31. doi: 10.1007/s40257-025-00968-2.
本文引用的文献
1
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21.
Zotero 插件